User profiles for J. Murai
Junko MuraiAssociate Professor, Ehime University Verified email at ehime-u.ac.jp Cited by 7574 |
The serum transport of steroid hormones
PK Siiteri, JT Murai, WJ RAYMOURE, RW KUHN… - Proceedings of the 1981 …, 1982 - Elsevier
Publisher Summary This chapter discusses the serum transport of steroid hormones. Steroid
hormones are extensively bound to plasma proteins including albumin, corticosteroid …
hormones are extensively bound to plasma proteins including albumin, corticosteroid …
Tyrosyl-DNA-phosphodiesterases (tdp1 and tdp2)
TDP1 and TDP2 were discovered and named based on the fact they process 3′- and 5′-DNA
ends by excising irreversible protein tyrosyl-DNA complexes involving topoisomerases I …
ends by excising irreversible protein tyrosyl-DNA complexes involving topoisomerases I …
Trapping of PARP1 and PARP2 by clinical PARP inhibitors
… Densitometric analyses of immunoblots were carried out using Image J software (NIH).
Further explanation of fractionation methods is available in the Supplementary Experimental …
Further explanation of fractionation methods is available in the Supplementary Experimental …
Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies
Schlafen 11 (SLFN11) sensitizes cells to a broad range of anti-cancer drugs including platinum
derivatives (cisplatin and carboplatin), inhibitors of topoisomerases (irinotecan, topotecan…
derivatives (cisplatin and carboplatin), inhibitors of topoisomerases (irinotecan, topotecan…
Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib
… Murai was a recipient of fellowships from the John Mung Program (Kyoto University) and the
… Murai was supported by JSPS KAKENHI Grant Number 25740016. J. Ji was supported by …
… Murai was supported by JSPS KAKENHI Grant Number 25740016. J. Ji was supported by …
A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress
Cisplatin and its platinum analogs, carboplatin and oxaliplatin, are some of the most widely
used cancer chemotherapeutics. Although cisplatin and carboplatin are used primarily in …
used cancer chemotherapeutics. Although cisplatin and carboplatin are used primarily in …
Rationale for poly (ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic …
We recently showed that poly(ADP-ribose) polymerase (PARP) inhibitors exert their
cytotoxicity primarily by trapping PARP-DNA complexes in addition to their NAD + -competitive …
cytotoxicity primarily by trapping PARP-DNA complexes in addition to their NAD + -competitive …
Interleukin-6 secretion in vitro is up-regulated in ectopic and eutopic endometrial stromal cells from women with endometriosis
JF Tseng, IP Ryan, TD Milam, JT Murai… - The Journal of …, 1996 - academic.oup.com
… (J Clin Endocrinol Metab 81: 1118-1122, … receptor synthesis in the cell cultures (Tseng, JF,
JT Murai, and RN Taylor, unpublished)… Halme J. 1989 Release of tumor necrosis factor-alpha …
JT Murai, and RN Taylor, unpublished)… Halme J. 1989 Release of tumor necrosis factor-alpha …
PARP1–TDP1 coupling for the repair of topoisomerase I–induced DNA damage
Poly(ADP-ribose) polymerases (PARP) attach poly(ADP-ribose) (PAR) chains to various
proteins including themselves and chromatin. Topoisomerase I (Top1) regulates DNA …
proteins including themselves and chromatin. Topoisomerase I (Top1) regulates DNA …
[HTML][HTML] Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
Poly (ADP-ribose) polymerase inhibitors (PARPIs) kill cancer cells by trapping PARP1 and
PARP2. Talazoparib, the most potent PARPI inhibitor (PARPI), exhibits remarkable selectivity …
PARP2. Talazoparib, the most potent PARPI inhibitor (PARPI), exhibits remarkable selectivity …